Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann
{"title":"以 CYP2C19 床旁药物遗传学为指导的抗血小板疗法加上多维治疗决策。","authors":"Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann","doi":"10.2217/pgs-2023-0200","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Implementation of <i>CYP2C19</i> point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. <b>Methods:</b> POC <i>CYP2C19</i> genotyping plus expert evaluation of risk factors for ischemic and bleeding events. <b>Results:</b> 167 patients underwent PGx testing, 54 (32.3%) were <i>CYP2C19</i> loss of function carriers, and POC versus standard PGx analysis results for <i>*2</i> and <i>*3</i> variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. <b>Conclusion:</b> <i>CYP2C19</i> POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antiplatelet therapy guided by <i>CYP2C19</i> point-of-care pharmacogenetics plus multidimensional treatment decisions.\",\"authors\":\"Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann\",\"doi\":\"10.2217/pgs-2023-0200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Implementation of <i>CYP2C19</i> point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. <b>Methods:</b> POC <i>CYP2C19</i> genotyping plus expert evaluation of risk factors for ischemic and bleeding events. <b>Results:</b> 167 patients underwent PGx testing, 54 (32.3%) were <i>CYP2C19</i> loss of function carriers, and POC versus standard PGx analysis results for <i>*2</i> and <i>*3</i> variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. <b>Conclusion:</b> <i>CYP2C19</i> POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0200\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0200","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions.
Aim: Implementation of CYP2C19 point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. Methods: POC CYP2C19 genotyping plus expert evaluation of risk factors for ischemic and bleeding events. Results: 167 patients underwent PGx testing, 54 (32.3%) were CYP2C19 loss of function carriers, and POC versus standard PGx analysis results for *2 and *3 variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. Conclusion:CYP2C19 POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
